SCH 23390 - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	SCH 23390	go back to main search page
Accession:	CHEBI:73297	browse the term
Definition:	A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 7 and a hydroxy substituent at position 8.
Synonyms:	exact_synonym:	8-chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol
	related_synonym:	7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol; Formula=C17H18ClNO; InChI=1S/C17H18ClNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3; InChIKey=GOTMKOSCLKVOGG-UHFFFAOYSA-N; SMILES=CN1CCc2cc(Cl)c(O)cc2C(C1)c1ccccc1
	xref_mesh:	MESH:C534628
	xref:	PMID:21242715; PMID:21864553; PMID:23123352; PMID:23320810; PMID:23597562; Reaxys:4323128; Wikipedia:SCH_23390

show annotations for term's descendants Sort by:
Rat (294) Mouse (291) Human (290) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (294)

SCH 23390

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 6

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily D member 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ABCD4 mRNA

NCBI chr 6:104,246,459...104,260,965
Ensembl chr 6:104,246,468...104,280,276

G

ATP binding cassette subfamily G member 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

actin-binding Rho activating protein

multiple interactions

[Methamphetamine co-treated with SCH 23390] affects the expression of ABRA mRNA

NCBI chr 7:72,970,187...72,974,255
Ensembl chr 7:72,970,186...72,974,255

G

acyl-CoA thioesterase 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of ADAMTS9 mRNA
SCH 23390 results in decreased expression of ADAMTS9 mRNA

NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929

G

adenylate cyclase 5

multiple interactions

SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Clozapine]; SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Haloperidol]

NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974

G

activator of HSP90 ATPase homolog 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of AHSA2 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of AHSA2 mRNA]

NCBI chr14:97,476,304...97,485,725
Ensembl chr14:97,476,817...97,485,657

G

allograft inflammatory factor 1

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased expression of AIF1 protein]

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ALG1 mRNA

NCBI chr10:10,346,538...10,356,768
Ensembl chr10:10,346,536...10,356,750

G

ankyrin repeat domain 44

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ANKRD44 mRNA
SCH 23390 results in decreased expression of ANKRD44 mRNA

NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508

G

apelin receptor

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of APLNR mRNA

NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050

G

apolipoprotein L domain containing 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of APOLD1 mRNA

NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706

G

activity-regulated cytoskeleton-associated protein

multiple interactions
decreases expression

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of ARC mRNA]
SCH 23390 results in decreased expression of ARC mRNA

PMID:11085305 PMID:19564919

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

ADP-ribosylation factor like GTPase 5B

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of ARL5B mRNA
SCH 23390 results in increased expression of ARL5B mRNA

NCBI chr17:77,955,864...77,979,895
Ensembl chr17:77,955,818...77,979,854

G

activating transcription factor 3

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of ATF3 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of ATF3 mRNA]
SCH 23390 results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of ATF4 mRNA]; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of ATF4 protein]

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

arginine vasopressin

affects expression
multiple interactions

SCH 23390 affects the expression of AVP mRNA
[Methamphetamine co-treated with SCH 23390] affects the expression of AVP mRNA

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

Beta-1,3-galactosyltransferase 4

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of B3GALT4 mRNA
SCH 23390 results in decreased expression of B3GALT4 mRNA

NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315

G

BCL2 associated X, apoptosis regulator

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein]
SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in decreased expression of BCL2 protein]

PMID:19879923 PMID:30922767

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 15

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of BCL2L15 mRNA

NCBI chr 2:191,338,959...191,344,078
Ensembl chr 2:191,338,959...191,344,078

G

BCL6, transcription repressor

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of BCL6 mRNA

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

betaine-homocysteine S-methyltransferase 2

affects expression
multiple interactions

SCH 23390 affects the expression of BHMT2 mRNA
[Methamphetamine co-treated with SCH 23390] affects the expression of BHMT2 mRNA

NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475

G

similar to human chromosome 16 open reading frame 89

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of C10H16ORF89 mRNA
SCH 23390 results in decreased expression of C10H16ORF89 mRNA

NCBI chr10:10,361,909...10,371,046
Ensembl chr10:10,361,948...10,371,046

G

similar to human chromosome 8 open reading frame 58

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of C15H8ORF58 mRNA
SCH 23390 results in decreased expression of C15H8ORF58 mRNA

NCBI chr15:45,228,615...45,235,274
Ensembl chr15:45,228,615...45,233,254

G

C1q and TNF related 7

decreases expression
multiple interactions

SCH 23390 results in decreased expression of C1QTNF7 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of C1QTNF7 mRNA

NCBI chr14:67,467,888...67,580,477
Ensembl chr14:67,468,014...67,580,410

G

similar to human chromosome 1 open reading frame 210

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of C5H1ORF210 mRNA

NCBI chr 5:132,048,755...132,051,913
Ensembl chr 5:132,048,773...132,051,925

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of CACNA2D1 mRNA]; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of CACNA2D1 protein]

NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969

G

calcitonin-related polypeptide alpha

multiple interactions

SCH 23390 inhibits the reaction [Dextroamphetamine results in increased expression of CALCA protein]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcium/calmodulin-dependent protein kinase II alpha

multiple interactions

SCH 23390 inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

carbonic anhydrase 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CAR4 mRNA

NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501

G

caspase 3

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

coiled-coil and C2 domain containing 1B

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CC2D1B mRNA

NCBI chr 5:123,353,289...123,367,343
Ensembl chr 5:123,353,292...123,367,318

G

coiled-coil domain containing 117

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of CCDC117 mRNA

NCBI chr14:80,399,236...80,409,824
Ensembl chr14:80,400,294...80,409,659

G

cellular communication network factor 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

C-C motif chemokine receptor 5

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD86 molecule

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased expression of CD86 mRNA]

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

SCH 23390 results in increased expression of CDKN1A mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CCAAT/enhancer binding protein beta

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

centrosomal protein 104

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CEP104 mRNA
SCH 23390 affects the expression of CEP104 mRNA

NCBI chr 5:164,534,773...164,567,260
Ensembl chr 5:164,534,782...164,567,248

G

cysteine and histidine rich domain containing 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of CHORDC1 mRNA

NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162

G

cholinergic receptor nicotinic beta 1 subunit

decreases expression

SCH 23390 results in decreased expression of CHRNB1 mRNA

NCBI chr10:54,501,096...54,516,418
Ensembl chr10:54,501,093...54,516,345

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of CHRNE mRNA
SCH 23390 results in increased expression of CHRNE mRNA

NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530

G

chromosome transmission fidelity factor 18

decreases expression
multiple interactions

SCH 23390 results in decreased expression of CHTF18 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of CHTF18 mRNA

NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CITED4 mRNA

NCBI chr 5:134,246,936...134,247,827
Ensembl chr 5:134,246,682...134,248,135

G

clavesin 2

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of CLVS2 mRNA
SCH 23390 results in decreased expression of CLVS2 mRNA

NCBI chr 1:23,735,660...23,842,685
Ensembl chr 1:23,735,272...23,842,692

G

CCR4-NOT transcription complex, subunit 6-like

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of CNOT6L mRNA
SCH 23390 results in increased expression of CNOT6L mRNA

NCBI chr14:13,410,499...13,502,511
Ensembl chr14:13,411,281...13,498,203

G

collagen type III alpha 1 chain

decreases expression

SCH 23390 results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

coenzyme Q10B

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

cAMP responsive element binding protein 1

multiple interactions

SCH 23390 inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[SK&F 82958 binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cAMP responsive element modulator

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of CREM mRNA

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

corticotropin releasing hormone

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of CRH mRNA; SCH 23390 affects the reaction [Cocaine affects the expression of CRH mRNA]
SCH 23390 results in increased expression of CRH mRNA

PMID:11597771 PMID:19564919

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cysteine-rich secretory protein LCCL domain containing 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CRISPLD1 mRNA

NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926

G

crystallin, alpha B

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of CRYAB mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of CRYAB mRNA]
SCH 23390 results in increased expression of CRYAB mRNA

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

cysteine and glycine-rich protein 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CSRP2 mRNA

NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745

G

CWC25 spliceosome-associated protein homolog

decreases expression

SCH 23390 results in decreased expression of CWC25 mRNA

NCBI chr10:82,735,698...82,760,373
Ensembl chr10:82,736,995...82,760,354

G

cytochrome P450, family 2, subfamily j, polypeptide 10

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CYP2J10 mRNA

NCBI chr 5:110,960,319...110,995,220
Ensembl chr 5:110,960,317...110,995,115

G

cysteine and tyrosine rich 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of CYYR1 mRNA

NCBI chr11:24,557,620...24,664,007
Ensembl chr11:24,515,316...24,663,961

G

defender against cell death 1

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DAD1 mRNA]

NCBI chr15:27,677,286...27,697,120
Ensembl chr15:27,677,268...27,697,347

G

DNA-damage inducible transcript 3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DDIT3 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DDIT3 mRNA]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

dermokine

decreases expression

SCH 23390 results in decreased expression of DMKN mRNA

NCBI chr 1:86,013,237...86,031,243
Ensembl chr 1:86,014,188...86,030,006

G

dynein, axonemal, heavy chain 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of DNAH1 mRNA

NCBI chr16:6,455,514...6,517,103
Ensembl chr16:6,456,002...6,518,350

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DNAJA1 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DNAJA1 mRNA]

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DNAJB1 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DNAJB1 mRNA]

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DNAJB5 mRNA]

NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490

G

DnaJ heat shock protein family (Hsp40) member C3

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of DNAJC3 mRNA]

NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181

G

deoxyribonuclease 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of DNASE1 mRNA

NCBI chr10:11,498,930...11,505,151
Ensembl chr10:11,498,931...11,501,869

G

docking protein 3

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of DOK3 mRNA
SCH 23390 results in increased expression of DOK3 mRNA

NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188

G

dopamine receptor D1

affects binding
multiple interactions
decreases activity

SCH 23390 binds to DRD1 protein
SCH 23390 inhibits the reaction [A 68930 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [A 86929 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 86929 results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; SCH 23390 inhibits the reaction [dihydrexidine results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [dinapsoline affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [dinapsoline results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [Isoquinolines affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Isoquinolines results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [SK&F 81297 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; SCH 23390 inhibits the reaction [SK&F 82958 affects the localization of DRD1 protein]
[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to A 86929; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to adrogolide hydrochloride; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methamphetamine; Amlodipine inhibits the reaction [SCH 23390 binds to DRD1 protein]; Diltiazem inhibits the reaction [SCH 23390 binds to DRD1 protein]; Flunarizine inhibits the reaction [SCH 23390 binds to DRD1 protein]; manidipine inhibits the reaction [SCH 23390 binds to DRD1 protein]; NR3C1 protein promotes the reaction [SCH 23390 binds to DRD1 protein]; SCH 23390 binds to and results in decreased activity of DRD1 protein; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; Verapamil inhibits the reaction [SCH 23390 binds to DRD1 protein]
8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine inhibits the reaction [SCH 23390 binds to DRD1 protein]; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to ethyl acetate]; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Cocaine results in increased expression of FOS protein]; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Methamphetamine results in increased expression of DUSP1 mRNA]; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Methamphetamine results in increased expression of DUSP6 mRNA]; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to A 86929; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Amphetamine; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methamphetamine; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methylphenidate; [SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Nicotine; Aluminum inhibits the reaction [SCH 23390 binds to DRD1 protein]; boldine analog inhibits the reaction [SCH 23390 binds to DRD1 protein]; Cadmium inhibits the reaction [SCH 23390 binds to DRD1 protein]; Cocaine affects the reaction [SCH 23390 binds to DRD1 protein]; Copper inhibits the reaction [SCH 23390 binds to DRD1 protein]; Dopamine deficiency inhibits the reaction [SCH 23390 binds to DRD1 protein]; Gadolinium inhibits the reaction [SCH 23390 binds to DRD1 protein]; Glyphosate inhibits the reaction [SCH 23390 binds to DRD1 protein]; Lanthanum inhibits the reaction [SCH 23390 binds to DRD1 protein]; Methamphetamine inhibits the reaction [SCH 23390 binds to DRD1 protein]; Pilocarpine inhibits the reaction [SCH 23390 binds to DRD1 protein]; SCH 23390 binds to and results in decreased activity of DRD1 protein; SCH 23390 inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[SK&F 82958 binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [A 86929 binds to and results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; SCH 23390 inhibits the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]; Zinc Acetate inhibits the reaction [SCH 23390 binds to DRD1 protein]; zinc chloride inhibits the reaction [SCH 23390 binds to DRD1 protein]; Zinc Sulfate inhibits the reaction [SCH 23390 binds to DRD1 protein]
SCH 23390 results in decreased activity of DRD1 protein
SCH 23390 binds to Drd1 protein

CTD
RGD

PMID:1418306 PMID:1724532 PMID:1833784 PMID:2213551 PMID:2891082 More...

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

G

dopamine receptor D2

multiple interactions

SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

multiple interactions

SCH 23390 inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dual specificity phosphatase 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of DUSP1 mRNA; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Methamphetamine results in increased expression of DUSP1 mRNA]

PMID:11701771 PMID:19564919

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 14

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of DUSP14 mRNA
SCH 23390 results in increased expression of DUSP14 mRNA

NCBI chr10:68,936,483...68,966,347
Ensembl chr10:68,935,330...68,965,329

G

dual specificity phosphatase 6

multiple interactions

[SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Methamphetamine results in increased expression of DUSP6 mRNA]

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

ephrin B1

increases expression

SCH 23390 results in increased expression of EFNB1 mRNA

NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157

G

EGF-like-domain, multiple 7

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of EGFL7 mRNA

NCBI chr 3:9,404,622...9,416,879
Ensembl chr 3:9,407,520...9,416,879

G

EGF-like, fibronectin type III and laminin G domains

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of EGFLAM mRNA

NCBI chr 2:56,301,945...56,476,665
Ensembl chr 2:56,302,566...56,476,298

G

early growth response 1

multiple interactions

SCH 23390 inhibits the reaction [[Reserpine co-treated with Levodopa] results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Dextroamphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Reserpine promotes the reaction [Dextroamphetamine results in increased expression of EGR1 mRNA]]

PMID:1347779 PMID:9890435 PMID:16549270

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

decreases expression

SCH 23390 results in decreased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

early growth response 4

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of EGR4 mRNA
SCH 23390 results in decreased expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased expression of EIF2AK3 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

ETS transcription factor ELK1

multiple interactions

SCH 23390 inhibits the reaction [Dronabinol results in increased phosphorylation of and results in increased activity of ELK1 protein]

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

epithelial cell adhesion molecule

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of EPCAM mRNA

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased expression of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ERBB receptor feedback inhibitor 1

increases expression
multiple interactions

SCH 23390 results in increased expression of ERRFI1 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

fatty acid amide hydrolase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of FAAH mRNA

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

Fas associated via death domain

increases expression

SCH 23390 results in increased expression of FADD protein

NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653

G

Fc gamma receptor 2A

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased expression of FCGR3 mRNA]

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

Fc gamma receptor 2B

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in increased expression of FCGR2B mRNA]

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

fibroblast growth factor 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of FGF4 mRNA

NCBI chr 1:200,023,937...200,027,793
Ensembl chr 1:200,024,056...200,025,466

G

flavin containing dimethylaniline monoxygenase 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of FMO2 mRNA
SCH 23390 results in increased expression of FMO2 mRNA

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of FOS mRNA; [Pilocarpine co-treated with SCH 23390] results in increased expression of FOS protein; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [Cocaine results in increased expression of FOS protein]; SCH 23390 inhibits the reaction [A 68930 results in increased expression of FOS mRNA]; SCH 23390 inhibits the reaction [Amphetamine results in increased expression of FOS protein]; SCH 23390 inhibits the reaction [Cocaine results in increased expression of FOS protein]; SCH 23390 inhibits the reaction [Dextroamphetamine results in increased expression of FOS mRNA]; SCH 23390 inhibits the reaction [dihydrexidine results in increased expression of FOS mRNA]
SCH 23390 results in decreased expression of FOS mRNA

PMID:2118661 PMID:8511714 PMID:8864302 PMID:9751140 PMID:11172061 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased expression of FOSB protein alternative form]; SCH 23390 inhibits the reaction [Cocaine results in increased expression of FOSB protein]
SCH 23390 inhibits the reaction [Amphetamine results in increased expression of FOSB mRNA]

PMID:16674926 PMID:18822274 PMID:19710318

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

formimidoyltransferase cyclodeaminase

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of FTCD mRNA
SCH 23390 results in increased expression of FTCD mRNA

NCBI chr20:12,055,203...12,068,717
Ensembl chr20:12,055,208...12,068,735

G

gamma-aminobutyric acid type A receptor subunit rho3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of GABRR3 mRNA

NCBI chr11:40,902,812...40,955,263
Ensembl chr11:40,902,812...40,955,263

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

growth arrest specific 8

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of GAS8 mRNA
SCH 23390 results in decreased expression of GAS8 mRNA

NCBI chr19:51,552,770...51,572,323
Ensembl chr19:51,552,816...51,572,305

G

growth differentiation factor 15

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GTP binding protein overexpressed in skeletal muscle

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] affects the expression of GEM mRNA
SCH 23390 results in decreased expression of GEM mRNA

NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222

G

glial fibrillary acidic protein

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of GFAP protein]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

GDNF family receptor alpha 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of GFRA4 mRNA

NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329

G

gap junction protein, alpha 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of GJA4 mRNA

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

G protein-coupled receptor 150

decreases expression
multiple interactions

SCH 23390 results in decreased expression of GPR150 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of GPR150 mRNA

NCBI chr 2:5,546,304...5,550,889
Ensembl chr 2:5,548,578...5,550,714

G

G protein-coupled receptor 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

G-protein coupled receptor 65

increases expression
multiple interactions

SCH 23390 results in increased expression of GPR65 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of GPR65 mRNA

NCBI chr 6:117,515,786...117,536,514
Ensembl chr 6:117,515,648...117,536,512

G

gametocyte specific factor 2

decreases expression
multiple interactions

SCH 23390 results in decreased expression of GTSF2 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of GTSF2 mRNA

NCBI chr 7:134,565,889...134,572,047
Ensembl chr 7:134,565,889...134,572,047

G

hypocretin neuropeptide precursor

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of HCRT mRNA
SCH 23390 results in decreased expression of HCRT mRNA

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

homocysteine inducible ER protein with ubiquitin like domain 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HERPUD1 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HERPUD1 mRNA]

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hes family bHLH transcription factor 5

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of HES5 mRNA

NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001

G

histone cluster 1 H4 family member B

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of HIST1H4B mRNA
SCH 23390 results in increased expression of HIST1H4B mRNA

NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370

G

high mobility group AT-hook 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

heme oxygenase 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HMOX1 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HMOX1 mRNA]; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

multiple interactions

SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of HOMER1 mRNA]

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

histidine rich calcium binding protein

decreases expression
multiple interactions

SCH 23390 results in decreased expression of HRC mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of HRC mRNA

NCBI chr 1:95,813,262...95,816,987
Ensembl chr 1:95,813,253...95,816,984

G

heat shock transcription factor 2 binding protein

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of HSF2BP mRNA
SCH 23390 results in decreased expression of HSF2BP mRNA

NCBI chr20:10,035,562...10,123,059
Ensembl chr20:10,035,562...10,121,242

G

heat shock protein family A (Hsp70) member 12B

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in decreased expression of HSPA12B mRNA]

NCBI chr 3:118,346,372...118,364,374
Ensembl chr 3:118,346,354...118,364,737

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HSPA5 mRNA; SCH 23390 inhibits the reaction [Cocaine results in increased expression of HSPA5 protein]; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HSPA5 mRNA]

PMID:17303341 PMID:19564919

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family B (small) member 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HSPB1 mRNA; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HSPB1 mRNA]

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family B (small) member 8

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of HSPB8 mRNA]

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

hyccin PI4KA lipid kinase complex subunit 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of HYCC2 mRNA

NCBI chr 9:60,056,883...60,129,176
Ensembl chr 9:60,056,890...60,093,007

G

intercellular adhesion molecule 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ICAM2 mRNA

NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293

G

Idnk, gluconokinase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of IDNK mRNA

NCBI chr17:6,483,575...6,490,780
Ensembl chr17:6,483,576...6,490,905

G

interleukin 10

multiple interactions

SCH 23390 inhibits the reaction [Reserpine results in decreased expression of IL10 mRNA]; SCH 23390 inhibits the reaction [Reserpine results in decreased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of IL1A mRNA
SCH 23390 results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interphotoreceptor matrix proteoglycan 1

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] affects the expression of IMPG1 mRNA
SCH 23390 results in decreased expression of IMPG1 mRNA

NCBI chr 8:81,243,624...81,389,722
Ensembl chr 8:81,243,624...81,389,722

G

IQ motif containing F1

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of IQCF1 mRNA
SCH 23390 results in increased expression of IQCF1 mRNA

NCBI chr 8:107,129,462...107,133,242
Ensembl chr 8:107,130,704...107,133,249

G

junction adhesion molecule like

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of JAML mRNA
SCH 23390 results in increased expression of JAML mRNA

NCBI chr 8:45,384,836...45,415,459
Ensembl chr 8:45,383,495...45,416,565

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of JUNB mRNA; SCH 23390 inhibits the reaction [Dextroamphetamine results in increased expression of JUNB mRNA]; SCH 23390 inhibits the reaction [Reserpine promotes the reaction [Dextroamphetamine results in increased expression of JUNB mRNA]]

PMID:1347779 PMID:19564919

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

kinesin family member 15

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of KIF15 mRNA
SCH 23390 results in decreased expression of KIF15 mRNA

NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750

G

KLF transcription factor 5

decreases expression

SCH 23390 results in decreased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

kelch-like family member 15

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of KLHL15 mRNA
SCH 23390 results in increased expression of KLHL15 mRNA

NCBI chr X:58,994,726...59,050,207
Ensembl chr X:58,995,461...59,046,069

G

keratin 7

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of KRT7 mRNA
SCH 23390 results in decreased expression of KRT7 mRNA

NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052

G

L3MBTL histone methyl-lysine binding protein 1

increases expression
multiple interactions

SCH 23390 results in increased expression of L3MBTL1 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of L3MBTL1 mRNA

NCBI chr 3:151,597,903...151,633,657
Ensembl chr 3:151,602,980...151,631,233

G

galectin 9

decreases expression
multiple interactions

SCH 23390 results in decreased expression of LGALS9 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of LGALS9 mRNA

NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045

G

leucine rich repeat containing 28

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of LRRC28 mRNA

NCBI chr 1:121,116,833...121,245,805
Ensembl chr 1:121,127,733...121,245,784

G

latent transforming growth factor beta binding protein 1

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of LTBP1 mRNA
SCH 23390 results in decreased expression of LTBP1 mRNA

NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349

G

leukotriene C4 synthase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of LTC4S mRNA

NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651

G

leukocyte receptor tyrosine kinase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of LTK mRNA

NCBI chr 3:106,734,675...106,741,552
Ensembl chr 3:106,734,676...106,743,369

G

leucine rich adaptor protein 1

decreases expression
multiple interactions

SCH 23390 results in decreased expression of LURAP1 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of LURAP1 mRNA

NCBI chr 5:129,618,926...129,628,651
Ensembl chr 5:129,614,137...129,628,766

G

LYR motif containing 9

decreases expression
multiple interactions

SCH 23390 results in decreased expression of LYRM9 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of LYRM9 mRNA

NCBI chr10:63,725,718...63,739,772
Ensembl chr10:63,725,743...63,739,772

G

MAF bZIP transcription factor F

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mesencephalic astrocyte-derived neurotrophic factor

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of MANF mRNA]

NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438

G

mitogen activated protein kinase 1

multiple interactions

SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]
SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein]; SCH 23390 inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

PMID:11553284 PMID:19187092 PMID:20956312

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein]; SCH 23390 inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

PMID:11553284 PMID:19187092 PMID:20956312

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule associated serine/threonine kinase-like

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] affects the expression of MASTL mRNA
SCH 23390 affects the expression of MASTL mRNA

NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353

G

melanocortin 4 receptor

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of MC4R mRNA

NCBI chr18:60,419,832...60,421,719
Ensembl chr18:60,419,832...60,421,719

G

minichromosome maintenance 8 homologous recombination repair factor

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of MCM8 mRNA
SCH 23390 results in decreased expression of MCM8 mRNA

NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008

G

major facilitator superfamily domain containing 10

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of MFSD10 mRNA

NCBI chr14:76,103,762...76,107,385
Ensembl chr14:76,103,815...76,107,377

G

MN1 proto-oncogene, transcriptional regulator

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of MN1 mRNA

NCBI chr12:45,181,794...45,220,959
Ensembl chr12:45,183,085...45,221,651

G

N-methylpurine-DNA glycosylase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of MPG mRNA

NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520

G

MUS81 structure-specific endonuclease subunit

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of MUS81 mRNA

NCBI chr 1:202,790,295...202,796,008
Ensembl chr 1:202,790,466...202,795,843

G

myosin light chain kinase

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] affects the expression of MYLK mRNA
SCH 23390 results in decreased expression of MYLK mRNA

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

Ngfi-A binding protein 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of NAB2 mRNA
SCH 23390 results in increased expression of NAB2 mRNA

NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989

G

N-deacetylase and N-sulfotransferase 3

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NDST3 mRNA
SCH 23390 results in decreased expression of NDST3 mRNA

NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584

G

neuralized E3 ubiquitin protein ligase 2

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NEURL2 mRNA
SCH 23390 results in decreased expression of NEURL2 mRNA

NCBI chr 3:153,566,659...153,569,380
Ensembl chr 3:153,566,660...153,569,380

G

nuclear factor of activated T-cells 3

affects expression
multiple interactions

SCH 23390 affects the expression of NFATC3 mRNA
SCH 23390 inhibits the reaction [Methamphetamine affects the localization of NFATC3 protein]

PMID:15644446 PMID:19564919

NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150

G

nuclear factor of activated T-cells 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NFATC4 mRNA; SCH 23390 inhibits the reaction [Methamphetamine affects the localization of NFATC4 protein]

PMID:15644446 PMID:19564919

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

NFE2 like bZIP transcription factor 2

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine affects the localization of NFE2L2 protein]; SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor, interleukin 3 regulated

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NFKB inhibitor alpha

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased activity of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NK2 homeobox 6

affects expression
multiple interactions

SCH 23390 affects the expression of NKX2-6 mRNA
[Methamphetamine co-treated with SCH 23390] affects the expression of NKX2-6 mRNA

NCBI chr15:44,443,151...44,447,248
Ensembl chr15:44,443,101...44,447,247

G

NK6 homeobox 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NKX6-2 mRNA

NCBI chr 1:194,380,149...194,383,533
Ensembl chr 1:194,381,975...194,383,515

G

NOTUM, palmitoleoyl-protein carboxylesterase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NOTUM mRNA

NCBI chr10:105,933,245...105,940,327
Ensembl chr10:105,933,249...105,940,315

G

neuronal PAS domain protein 4

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of NPAS4 mRNA

NCBI chr 1:202,281,260...202,298,681
Ensembl chr 1:202,281,958...202,286,724

G

neuronal pentraxin 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of NPTX2 mRNA

NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345

G

neuropeptide Y

increases expression
multiple interactions

SCH 23390 results in increased expression of NPY protein
[Prazosin co-treated with SCH 23390] inhibits the reaction [Phenylpropanolamine results in decreased expression of NPY protein]

PMID:7644023 PMID:21989786

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

NR3C1 protein promotes the reaction [SCH 23390 binds to DRD1 protein]

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of NR4A2 mRNA
SCH 23390 results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nuclear receptor subfamily 4, group A, member 3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of NR4A3 mRNA

NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733

G

nurim

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of NRM mRNA

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

nucleoporin 210-like

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of NUP210L mRNA
SCH 23390 results in increased expression of NUP210L mRNA

NCBI chr 2:175,545,999...175,665,332
Ensembl chr 2:175,547,988...175,665,332

G

obscurin like cytoskeletal adaptor 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of OBSL1 mRNA

NCBI chr 9:76,967,802...76,993,771
Ensembl chr 9:76,974,253...76,993,560

G

8-oxoguanine DNA glycosylase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of OGG1 mRNA

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

olfactory receptor family 14 subfamily J member 3D

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of OR14J3D mRNA
SCH 23390 results in increased expression of OR14J3D mRNA

NCBI chr20:872,996...873,910
Ensembl chr20:833,838...846,753

G

olfactory receptor family 1 subfamily O member 11C

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of OR1O11C mRNA
SCH 23390 results in increased expression of OR1O11C mRNA

NCBI chr20:1,097,181...1,098,110
Ensembl chr20:1,097,181...1,098,110

G

oxoglutarate receptor 1

increases expression
multiple interactions

SCH 23390 results in increased expression of OXGR1 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of OXGR1 mRNA

NCBI chr15:97,145,947...97,146,960
Ensembl chr15:97,144,293...97,166,612

G

oxytocin/neurophysin I prepropeptide

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] affects the expression of OXT mRNA
SCH 23390 affects the expression of OXT mRNA

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

prolyl 4-hydroxylase subunit alpha 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

prolyl 4-hydroxylase subunit alpha 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of P4HA2 mRNA
SCH 23390 results in increased expression of P4HA2 mRNA

NCBI chr10:38,243,136...38,271,983
Ensembl chr10:38,243,139...38,287,314

G

peptidyl arginine deiminase 6

decreases expression
multiple interactions

SCH 23390 results in decreased expression of PADI6 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of PADI6 mRNA

NCBI chr 5:153,021,855...153,037,443
Ensembl chr 5:153,021,965...153,037,414

G

par-6 family cell polarity regulator gamma

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] affects the expression of PARD6G mRNA
SCH 23390 affects the expression of PARD6G mRNA

NCBI chr18:73,497,992...73,565,048
Ensembl chr18:73,498,021...73,565,029

G

PCNA clamp associated factor

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

proprotein convertase subtilisin/kexin type 1

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PCSK1 mRNA
SCH 23390 affects the expression of PCSK1 mRNA

NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434

G

phosphodiesterase 8A

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PDE8A mRNA

NCBI chr 1:135,166,143...135,288,986
Ensembl chr 1:135,166,237...135,288,024

G

protein disulfide isomerase family A, member 4

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PDIA4 mRNA]

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

pyruvate dehydrogenase kinase 4

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of PDK4 mRNA
SCH 23390 results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

phosphatidylethanolamine N-methyltransferase

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PEMT mRNA
SCH 23390 results in decreased expression of PEMT mRNA

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

post-GPI attachment to proteins 6

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PGAP6 mRNA

NCBI chr10:15,138,918...15,148,431
Ensembl chr10:15,138,959...15,148,431

G

phosphoinositide-3-kinase, regulatory subunit 5

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PIK3R5 mRNA

NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374

G

phosphoinositide-3-kinase, regulatory subunit 6

increases expression
multiple interactions

SCH 23390 results in increased expression of PIK3R6 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of PIK3R6 mRNA

NCBI chr10:53,203,930...53,255,229
Ensembl chr10:53,205,496...53,255,243

G

paired-like homeodomain 3

decreases expression
multiple interactions

SCH 23390 results in decreased expression of PITX3 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of PITX3 mRNA

NCBI chr 1:245,001,106...245,013,881
Ensembl chr 1:245,001,164...245,013,892

G

plakophilin 2

increases expression
multiple interactions

SCH 23390 results in increased expression of PKP2 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of PKP2 mRNA

NCBI chr11:84,661,783...84,727,730
Ensembl chr11:84,661,783...84,727,730

G

phospholipase A1 member A

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of PLA1A mRNA

NCBI chr11:62,320,112...62,357,779
Ensembl chr11:62,320,493...62,357,779

G

PLAG1 like zinc finger 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of PLAGL1 mRNA

NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228

G

plasminogen activator, tissue type

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of PLAT mRNA
SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PLAT mRNA]

PMID:15659235 PMID:19564919

NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223

G

pleckstrin homology and FYVE domain containing 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of PLEKHF1 mRNA

NCBI chr 1:90,908,304...90,915,862
Ensembl chr 1:90,904,742...90,915,820

G

pro-melanin-concentrating hormone

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] affects the expression of PMCH mRNA
SCH 23390 affects the expression of PMCH mRNA

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

diphosphoinositol pentakisphosphate kinase 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of PPIP5K2 mRNA

NCBI chr 9:98,315,220...98,394,537
Ensembl chr 9:98,315,252...98,390,814

G

protein phosphatase 1, regulatory subunit 15A

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PPP1R15A mRNA]

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171

G

protein phosphatase 3 catalytic subunit alpha

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PPP3CA protein]

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

protein phosphatase 3 catalytic subunit beta

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PPP3CB protein]

NCBI chr15:3,759,950...3,804,976
Ensembl chr15:3,760,030...3,804,981

G

protein phosphatase 3, regulatory subunit B, beta

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of PPP3R2 protein]

NCBI chr 5:64,026,903...64,027,898
Ensembl chr 5:64,026,903...64,032,548

G

proteoglycan 4

affects expression
multiple interactions

SCH 23390 affects the expression of PRG4 mRNA
[Methamphetamine co-treated with SCH 23390] affects the expression of PRG4 mRNA

NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119

G

protein kinase cAMP-dependent X-linked catalytic subunit

increases expression

SCH 23390 results in increased expression of PRKX mRNA

NCBI chr X:41,823,349...41,866,844
Ensembl chr X:41,823,355...41,866,669

G

prokineticin 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of PROK2 mRNA
SCH 23390 results in increased expression of PROK2 mRNA

NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385

G

prominin 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PROM1 mRNA

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

parathyroid hormone 1 receptor

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PTH1R mRNA

NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729

G

PYD and CARD domain containing

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of PYCARD mRNA
SCH 23390 results in decreased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RAB3D, member RAS oncogene family

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RAB3D mRNA

NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185

G

ras related dexamethasone induced 1

increases expression

SCH 23390 results in increased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

RAS-like family 11 member A

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RASL11A mRNA

NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576

G

Ras association domain family member 9

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RASSF9 mRNA

NCBI chr 7:37,599,720...37,631,553
Ensembl chr 7:37,599,720...37,635,245

G

RNA binding motif protein 3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RBM3 mRNA

NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580

G

RNA binding motif protein 43

decreases expression
multiple interactions

SCH 23390 results in decreased expression of RBM43 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of RBM43 mRNA

NCBI chr 3:36,394,431...36,404,757
Ensembl chr 3:36,395,346...36,404,816

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

SCH 23390 inhibits the reaction [Cocaine results in increased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

regulator of G-protein signaling 1

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] affects the expression of RGS1 mRNA
SCH 23390 affects the expression of RGS1 mRNA

NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984

G

regulator of G-protein signaling 2

multiple interactions

SCH 23390 inhibits the reaction [Amphetamine results in increased expression of RGS2 mRNA]

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

regulator of G-protein signaling 4

affects expression
multiple interactions
increases expression

SCH 23390 affects the expression of RGS4 protein
Dextroamphetamine promotes the reaction [SCH 23390 results in increased expression of RGS4 mRNA]

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

G

rhomboid 5 homolog 1

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RHBDF1 mRNA
SCH 23390 results in decreased expression of RHBDF1 mRNA

NCBI chr10:15,406,832...15,419,765
Ensembl chr10:15,406,859...15,419,763

G

ras homolog family member D

multiple interactions

[Methamphetamine co-treated with SCH 23390] affects the expression of RHOD mRNA

NCBI chr 1:201,708,699...201,724,405
Ensembl chr 1:201,708,699...201,722,632

G

RNA sensor RIG-1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RIGI mRNA

NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819

G

regulating synaptic membrane exocytosis 2

increases expression
multiple interactions

SCH 23390 results in increased expression of RIMS2 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of RIMS2 mRNA

NCBI chr 7:70,248,104...70,759,134
Ensembl chr 7:70,243,872...70,757,491

G

ripply transcriptional repressor 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RIPPLY2 mRNA

NCBI chr 8:87,974,444...87,979,002
Ensembl chr 8:87,974,776...87,978,969

G

ring finger protein 225

decreases expression
multiple interactions

SCH 23390 results in decreased expression of RNF225 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of RNF225 mRNA

NCBI chr 1:73,543,598...73,546,269
Ensembl chr 1:73,543,598...73,546,269

G

ribosomal protein S6 kinase A5

multiple interactions

SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein]

NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224

G

RNA pseudouridine synthase D3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RPUSD3 mRNA

NCBI chr 4:146,553,743...146,562,789
Ensembl chr 4:146,558,562...146,562,794

G

receptor (chemosensory) transporter protein 1

multiple interactions
affects expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of RTP1 mRNA
SCH 23390 affects the expression of RTP1 mRNA

NCBI chr11:77,422,982...77,425,498
Ensembl chr11:77,422,982...77,425,498

G

ryanodine receptor 1

multiple interactions

SCH 23390 inhibits the reaction [SK&F 82958 results in increased expression of RYR1 protein]

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

ryanodine receptor 2

multiple interactions

SCH 23390 inhibits the reaction [SK&F 82958 results in increased expression of RYR2 protein]

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A11

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of S100A11 mRNA
SCH 23390 results in decreased expression of S100A11 mRNA

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

serpin family B member 9

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SERPINB9 mRNA

NCBI chr17:31,420,118...31,443,237
Ensembl chr17:31,420,125...31,443,230

G

SERTA domain containing 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of SERTAD1 mRNA

NCBI chr 1:82,775,692...82,778,961
Ensembl chr 1:82,775,252...82,779,091

G

secreted frizzled-related protein 2

decreases expression
multiple interactions

SCH 23390 results in decreased expression of SFRP2 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of SFRP2 mRNA

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

serum/glucocorticoid regulated kinase 1

increases expression
multiple interactions

SCH 23390 results in increased expression of SGK1 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

single Ig and TIR domain containing

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SIGIRR mRNA

NCBI chr 1:196,195,363...196,208,692
Ensembl chr 1:196,199,462...196,202,269

G

sigma non-opioid intracellular receptor 1

multiple interactions

SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; SCH 23390 inhibits the reaction [Cocaine promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; SCH 23390 inhibits the reaction [SK&F 81297 promotes the reaction [[SIGMAR1 protein binds to DRD1 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]]

NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017

G

salt-inducible kinase 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of SIK1 mRNA

NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991

G

SIX homeobox 4

decreases expression
multiple interactions

SCH 23390 results in decreased expression of SIX4 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of SIX4 mRNA

NCBI chr 6:91,802,328...91,816,002
Ensembl chr 6:91,802,329...91,815,992

G

solute carrier family 16, member 11

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC16A11 mRNA
SCH 23390 results in decreased expression of SLC16A11 mRNA

NCBI chr10:54,929,129...54,933,021
Ensembl chr10:54,927,725...54,942,915

G

solute carrier family 16, member 13

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC16A13 mRNA

NCBI chr10:54,925,973...54,937,860
Ensembl chr10:54,926,760...54,937,788

G

solute carrier family 18 member A2

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in decreased expression of SLC18A2 protein]

NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325

G

solute carrier family 22 member 13

decreases expression
multiple interactions

SCH 23390 results in decreased expression of SLC22A13 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC22A13 mRNA

NCBI chr 8:118,922,367...118,934,020
Ensembl chr 8:118,922,367...118,953,635

G

solute carrier family 35 member B2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC35B2 mRNA

NCBI chr 9:15,438,594...15,442,227
Ensembl chr 9:15,438,594...15,442,234

G

solute carrier family 38, member 5

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC38A5 mRNA

NCBI chr X:14,213,727...14,222,498
Ensembl chr X:14,213,729...14,222,498

G

solute carrier family 39 member 12

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of SLC39A12 mRNA

NCBI chr17:77,353,761...77,440,384
Ensembl chr17:77,353,805...77,440,353

G

solute carrier family 40 member 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC40A1 mRNA

NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481

G

solute carrier family 5 member 3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 66 member 1

decreases expression
multiple interactions

SCH 23390 results in decreased expression of SLC66A1 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC66A1 mRNA

NCBI chr 5:151,537,870...151,552,259
Ensembl chr 5:151,542,376...151,552,259

G

solute carrier family 6 member 13

decreases expression
multiple interactions

SCH 23390 results in decreased expression of SLC6A13 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of SLC6A13 mRNA

NCBI chr 4:154,539,246...154,577,784
Ensembl chr 4:154,540,468...154,576,152

G

solute carrier family 6 member 3

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in decreased expression of SLC6A3 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

SMAD family member 3

increases expression
multiple interactions

SCH 23390 results in increased expression of SMAD3 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of SMAD3 mRNA

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

sorting nexin 27

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of SNX27 mRNA alternative form]

NCBI chr 2:182,135,904...182,218,906
Ensembl chr 2:182,135,905...182,218,906

G

SRY-box transcription factor 17

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SOX17 mRNA

NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228

G

SRY-box transcription factor 18

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SOX18 mRNA

NCBI chr 3:168,785,488...168,787,290
Ensembl chr 3:168,785,490...168,787,290

G

sperm acrosome associated 9

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SPACA9 mRNA
SCH 23390 results in decreased expression of SPACA9 mRNA

NCBI chr 3:12,019,376...12,028,801
Ensembl chr 3:12,019,363...12,029,119

G

sperm associated antigen 8

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SPAG8 mRNA

NCBI chr 5:57,901,681...57,903,894
Ensembl chr 5:57,901,682...57,903,894

G

spermatogenesis associated 6-like

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of SPATA6L mRNA

NCBI chr 1:226,630,470...226,682,979
Ensembl chr 1:226,641,518...226,682,884

G

ST13, Hsp70 interacting protein

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of ST13 mRNA]

NCBI chr 7:112,891,007...112,925,727
Ensembl chr 7:112,844,375...112,925,945

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ST8SIA6 mRNA

NCBI chr17:76,740,755...76,884,178
Ensembl chr17:76,745,224...76,884,299

G

STEAP family member 1

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of STEAP1 mRNA
SCH 23390 results in increased expression of STEAP1 mRNA

NCBI chr 4:28,276,972...28,287,484
Ensembl chr 4:28,276,909...28,287,479

G

signaling receptor and transporter of retinol STRA6

affects expression

SCH 23390 affects the expression of STRA6 mRNA

NCBI chr 8:58,548,899...58,568,861
Ensembl chr 8:58,549,736...58,568,860

G

synaptic vesicle glycoprotein 2c

increases expression
multiple interactions

SCH 23390 results in increased expression of SV2C mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of SV2C mRNA

NCBI chr 2:27,232,933...27,428,479
Ensembl chr 2:27,232,933...27,428,477

G

SWT1 RNA endoribonuclease homolog

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of SWT1 mRNA

NCBI chr13:63,452,494...63,509,982
Ensembl chr13:63,452,496...63,509,980

G

synaptotagmin 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] affects the expression of SYT2 mRNA
SCH 23390 results in increased expression of SYT2 mRNA

NCBI chr13:46,088,046...46,197,976
Ensembl chr13:46,185,282...46,193,859

G

taste 1 receptor member 1

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TAS1R1 mRNA
SCH 23390 results in decreased expression of TAS1R1 mRNA

NCBI chr 5:162,533,838...162,546,408
Ensembl chr 5:162,533,841...162,545,562

G

tectorin alpha

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TECTA mRNA

NCBI chr 8:42,707,962...42,779,726
Ensembl chr 8:42,707,962...42,779,707

G

terminal nucleotidyltransferase 5A

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of TENT5A mRNA

NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045

G

telomeric repeat binding factor 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TERF1 mRNA

NCBI chr 5:3,443,103...3,472,377
Ensembl chr 5:3,443,106...3,472,340

G

tyrosine hydroxylase

multiple interactions

SCH 23390 inhibits the reaction [1-(2-thienyl)-2-(methylamino)propane results in decreased expression of TH protein]; SCH 23390 inhibits the reaction [Methamphetamine results in decreased expression of TH protein]

PMID:16088948 PMID:30922767

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tyrosine kinase with immunoglobulin-like and EGF-like domains 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TIE1 mRNA

NCBI chr 5:132,000,013...132,019,658
Ensembl chr 5:132,000,015...132,019,592

G

toll-like receptor 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

transmembrane protein 123

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TMEM123 mRNA

NCBI chr 8:4,922,077...4,952,228
Ensembl chr 8:4,922,098...4,952,224

G

transmembrane protein 125

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TMEM125 mRNA

NCBI chr 5:132,063,162...132,064,566
Ensembl chr 5:132,059,554...132,079,297
Ensembl chr 5:132,059,554...132,079,297

G

transmembrane protein 18

decreases expression
multiple interactions

SCH 23390 results in decreased expression of TMEM18 mRNA
[Methamphetamine co-treated with SCH 23390] results in decreased expression of TMEM18 mRNA

NCBI chr 6:47,206,845...47,214,294
Ensembl chr 6:47,206,845...47,214,294

G

transmembrane protein 252

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of TMEM252 mRNA
SCH 23390 results in increased expression of TMEM252 mRNA

NCBI chr 1:222,316,982...222,321,946
Ensembl chr 1:222,316,795...222,321,943

G

transmembrane O-mannosyltransferase targeting cadherins 3

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TMTC3 mRNA
SCH 23390 results in increased expression of TMTC3 mRNA

NCBI chr 7:35,264,886...35,310,010
Ensembl chr 7:35,264,892...35,310,385

G

TSC22 domain family, member 3

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

Ttk protein kinase

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin tyrosine ligase like 9

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of TTLL9 mRNA

NCBI chr 3:141,429,351...141,475,965
Ensembl chr 3:141,429,444...141,475,865

G

ubiquitin-like modifier activating enzyme 2

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of UBA2 mRNA
SCH 23390 results in increased expression of UBA2 mRNA

NCBI chr 1:86,775,239...86,802,685
Ensembl chr 1:86,775,244...86,802,682

G

uridine phosphorylase 1

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of UPP1 mRNA

NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462

G

ubiquitin specific peptidase like 1

increases expression
multiple interactions

SCH 23390 results in increased expression of USPL1 mRNA
[Methamphetamine co-treated with SCH 23390] results in increased expression of USPL1 mRNA

NCBI chr12:5,823,460...5,850,470
Ensembl chr12:5,823,359...5,850,366

G

vascular endothelial growth factor A

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

X-box binding protein 1

multiple interactions

SCH 23390 inhibits the reaction [Methamphetamine results in increased splicing of XBP1 mRNA]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

Y box binding protein 1

multiple interactions
increases expression

[Methamphetamine co-treated with SCH 23390] results in increased expression of YBX1 mRNA
SCH 23390 results in increased expression of YBX1 mRNA

NCBI chr 5:132,882,137...132,898,885
Ensembl chr 5:132,882,145...132,898,862

G

zinc finger protein 189

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of ZFP189 mRNA

NCBI chr 5:63,872,596...63,884,348
Ensembl chr 5:63,872,738...63,884,121

G

zinc finger protein 287

multiple interactions
decreases expression

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ZFP287 mRNA
SCH 23390 results in decreased expression of ZFP287 mRNA

NCBI chr10:47,395,650...47,415,610
Ensembl chr10:47,397,285...47,439,755

G

zinc finger protein 36

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in increased expression of ZFP36 mRNA

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564

G

zinc finger protein 688

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ZFP688 mRNA

NCBI chr 1:182,039,366...182,043,035
Ensembl chr 1:182,039,931...182,043,103

G

Zic family member 2

multiple interactions

[Methamphetamine co-treated with SCH 23390] results in decreased expression of ZIC2 mRNA

NCBI chr15:99,576,697...99,581,522
Ensembl chr15:99,576,697...99,581,522

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19841
role	19817
biological role	19815
pharmacological role	19058
antagonist	17239
dopaminergic antagonist	1637
SCH 23390	294
Path 2
Term	Annotations
CHEBI ontology	19841
subatomic particle	19839
composite particle	19839
hadron	19839
baryon	19839
nucleon	19839
atomic nucleus	19839
atom	19839
main group element atom	19789
main group molecular entity	19789
s-block molecular entity	19626
hydrogen molecular entity	19613
hydrides	19120
inorganic hydride	18118
pnictogen hydride	18107
nitrogen hydride	18014
azane	17824
ammonia	17823
organic amino compound	17823
tertiary amino compound	10142
SCH 23390	294

paths to the root